Theratechnologies Investor Relations Material
Latest events
AGM 2025
Theratechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Theratechnologies Inc
Access all reports
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in cardiology, oncology, and women's health. The company primarily develops peptide-based therapeutics. Its product candidates include Onbrez Breezhaler, which is in Phase III clinical trial for the symptomatic relief of chronic obstructive pulmonary disease; and Theratears for Atopic Keratoconjunctivitis (MK), which is under Phase III clinical trial for the treatment of atopic keratoconjunctivitis. Theratechnologies Inc is headquartered in Montreal, Canada.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
TH
Country
🇨🇦 Canada